Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 9, 2009
Last updated: April 9, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)